Impact of orlistat initiation … [Eur J

Impact of orlistat initiation … [Eur J Cardiovasc Prev Rehabil. 2011] – PubMed – NCBI http://ow.ly/9nIUu
Eur J Cardiovasc Prev Rehabil. 2011 Apr 4. [Epub ahead of print]
Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.
Czernichow S, Knol MJ, Fezeu L, Grobbee DE.
Source
UMR (U557 INSERM, U1125 INRA, CNAM, Université Paris 13), CRNH-IdF, France; Université Paris 13; Hôpital Avicenne, Département de Santé Publique, France.
Abstract
Background: Trials of weight-loss drugs indicate some benefits on lipids, blood glucose, or blood pressure levels. Since obesity is associated with increased cardiovascular (CV) medication use and pharmaceutical costs, weight-loss drug use could beneficially impact CV medication use. Objective: We examined the temporal associations between CV drugs use 3 years before and after the initiation of orlistat, a weight-loss drug. Design: An historical cohort study in the PHARMO pharmacy registry among new users of orlistat, who were in the database at least 3 years before and after such drug initiation. We assessed the prevalence of use of antihypertensive, antidiabetic, and lipid-lowering drugs within a 6-month period before and after orlistat initiation. Slopes and changes in slopes between these two periods were calculated using logistic generalized estimating equations and odds ratios (OR) with 95% confidence intervals (CI) are presented. Results: A total of 6139 subjects had a prescription of orlistat between January 1992 and May 2009. Mean ± SD age was 46.5 ± 12.5 years, with a majority of female (88.7%). Use of antihypertensive, antidiabetic, and lipid-lowering drugs increased over time, but after start of orlistat the slopes levelled-off. Initiation of orlistat resulted in a significant change in slope for antihypertensive (OR 0.79; 95% CI 0.77-0.81), antidiabetic (0.86; 0.83-0.90), and lipid-lowering drugs (0.84; 0.81-0.88). Conclusions: Our data suggest a potential cost-effectiveness of orlistat, with a reduction in any cardiovascular comedication use over time. By potentially reducing costs of other medications use, orlistat remains as a unique option for tackling the obesity epidemic.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s